Form 4: Altimmune Chief Scientific Officer Reports Stock Transactions

M. Scot Roberts, Chief Scientific Officer of Altimmune, Inc., reported the acquisition of restricted stock units and stock options, as well as the disposition of shares to cover taxes.

Summary

• M. Scot Roberts, the Chief Scientific Officer of Altimmune, Inc., filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• On January 25, 2025, Roberts acquired 14,600 restricted stock units (RSUs) at no cost and disposed of 4,264 shares to cover taxes related to vesting RSUs at a price of $6.98 per share.
• Following these transactions, Roberts directly owns 53,646 shares of common stock and indirectly owns 15 shares through his spouse.
• On January 27, 2025, Roberts was granted 183,600 stock options with an exercise price of $7 and 63,400 restricted stock units.
• The RSUs vest over four years, and the stock options vest over a period starting January 27, 2026.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and insider transactions, which are generally neutral to positive. The vesting schedules and equity grants are positive for long-term alignment.

Positives

• The grant of stock options and restricted stock units to the Chief Scientific Officer aligns his interests with the long-term success of the company.
• The vesting schedule of the equity awards encourages continued service and commitment from the executive.

Negatives

• The sale of shares to cover taxes, while a common practice, slightly reduces the executive's direct shareholding.

Risks

• The vesting of the stock options and restricted stock units is contingent on the executive's continued service, which could pose a risk if the executive were to leave the company.
• The value of the stock options is dependent on the future performance of the company's stock price.

Future Outlook

The document does not contain any specific forward-looking statements about the company's future performance, but it does detail the vesting schedules for the equity awards.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in publicly traded companies. It provides transparency into the equity holdings of key executives.

Comparison to Industry Standards

• The vesting schedules for the restricted stock units and stock options are typical for executive compensation packages in the biotechnology industry.
• The use of RSUs and stock options is a standard practice to incentivize and retain key personnel in growth-oriented companies.
• The tax-related share disposals are a common occurrence when RSUs vest, and the price of $6.98 is reflective of the market price at the time of the transaction.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect standard executive compensation practices.
• The equity grants incentivize the Chief Scientific Officer to contribute to the company's long-term success.

Key Dates

Keywords

Form 4, insider trading, stock options, restricted stock units, beneficial ownership, equity compensation, Altimmune, M. Scot Roberts